Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Market Acea Biosciences' Cell Assay Technology

NEW YORK (GenomeWeb News) – Roche Applied Science has licensed exclusive rights to market systems for real-time cell analysis based on Acea Biosciences’ impedance-based technology, the firms announced today.
The technology is being developed for applications including short-term kinetic analysis and for assays for cell proliferation, cytotoxicity, and cell migration and invasion. According to San Diego-based Acea, its technology offers a label-free system, real-time kinetics, live cell quality control, and high information content.
“After completing our product portfolio in DNA/RNA analysis with 454 and NimbleGen, the Acea technology will be an essential cornerstone to strengthen and further extend our product portfolio in cell analysis,” Manfred Baier, head of Roche Applied Science, said in a statement.
Financial terms of the agreement were not disclosed.

The Scan

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.